Rosuvastatin

Rosuvastatin Impurities

Rosuvastatin impurities include process-related compounds, synthetic intermediates, degradation products, and potential nitrosamine contaminants that may arise during synthesis, formulation, or storage. As a potent HMG-CoA reductase inhibitor used to lower LDL cholesterol and reduce cardiovascular risk, impurity profiling is essential for ensuring product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Rosuvastatin EP Impurities

Pharmacopeial and non-pharmacopeial Rosuvastatin impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials are supplied with validated analytical data including purity, structural confirmation, and spectral characterization.

Rosuvastatin Related Compounds

Structurally related compounds and synthetic analogs associated with Rosuvastatin are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.

Rosuvastatin Impurity Reference Standards

Rosuvastatin impurity reference standards are provided with validated analytical data including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.